Australian digital health company ResApp Health Limited has received approval for the latest version of the world’s first smartphone-based diagnostic test for respiratory disease for both adults and children. This extends existing approval and adds the ability to test adults for lower respiratory tract disease, pneumonia, asthma exacerbation and chronic obstructive pulmonary disease exacerbation. This certification also allows the sale of this app throughout the European Economic Area. | http://bit.ly/33boyLp

AstraZeneca will partner with Schr?dinger to use the company's advanced computing platform to accelerate drug discovery efforts. Work conducted by AstraZeneca's medicinal and computational chemists will be used by Schr?dinger's computational platform to improve the design of compounds. In turn, this will identify potential new therapeutic candidates. Machine learning systematically analyses data to find connections with the artificial intelligence used to deduce previously unknown connections. Results are then used to gain a better understanding of the mechanisms of disease and the compounds that can treat them. https://www.biospace.com/article/astrazeneca-bolsters-machine-learning-use-for-drug-development-with-schro

Global research-based biopharmaceutical company AbbVie has announced U.S FDA approval for their new therapy for adults with moderately to severely active rheumatoid arthritis (RA). RINVOQ is a once-daily (15mg) oral Janus kinase inhibitor supported by data from the SELECT program - one of the largest registrational Phase 3 programs in RA. Approximately 4,400 patients were evaluated across all treatment arms in five studies. The company says that RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal. https://urlzs.com/SxYV2

Australian company Nanosonics have launched the latest innovation in ultrasound probe high-level disinfection: Trophon?2. A fully automated process for the decontamination of ultrasound probes, Trophon2 is safe for the environment, users and most importantly patients. Full decontamination and traceability occurs within seven minutes with the press of a button. https://www.nanosonics.com.au/trophon2/

Australia-based gut health biotech company Microba has launched a research and development program to develop gut microbiome derived therapeutics for IBD. Microba has identified distinct differences in the gut microbiome of healthy individuals and those with IBD. Using deep learning artificial intelligence, their scientists are now able to predict IBD in patients from microbiome data alone with 86% accuracy. The program aims to create novel therapeutics that will rapidly induce and maintain remission in those with IBD. Microba launched the program at BIO in Philadelphia with the Queensland Minister for Innovation, The Hon. Kate Jones in June. | http://bit.ly/2T5B37F

SoeMac is an alternative treatment for people with respiratory and sleep disorders. It is a CE marked, Class I Medical Device, that uses patent protected technology to produce and deliver a beneficial form of Oxygen Energy for the body to use. Typical health benefits include; easier and deeper breathing and clearance of excess mucus, a deeper and better quality of sleep, more energy to go about the daily tasks, and an increase in the user's positivity. There is no mask or canula. The SoeMac is located on the bedside table, and runs each and every night. There are already thousands of satisfied customers, and a formal controlled Clinical Study is currently underway in the East Midlands, with health professionals and academics. www.soemac.com .